home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

1st Information Day on the Development Safety Update Report (DSUR) Guidelines ICH E2F

 
  May 23, 2011  
     
 
European Medicines Agency , London, UK
Jul 4 2011 9:00AM - 5:00PM


This is a repetition of the Information Day that took place on 23 March 2011.

The new ICH guidelines E2F on the Development Safety Update Report (DSUR) has been signed off in August 2010 and will come into force in September 2011 in the European Economic Area (EEA). It is very likely that this new report will replace the current Annual Safety Report for clinical trials. This Information Day is intended to introduce the new DSUR concept. The structure and content will be described and explained by the European experts, who actively participated in the development of the ICH E2F guideline. Practical aspects based on DSUR examples for commercial and non-commercial sponsors will be presented. Finally, planning and organisational aspects will be discussed as to when and how the DSUR will be implemented in the EEA. Attendees will be provided with the opportunity to raise questions and to actively engage in the panel discussions with all the speakers.

 

Payment of registration fees must be received before commencement of the event.

Event Code:
11591

 

 
 
Organized by: DIA Europe
Invited Speakers: See website for speaker information
 
Deadline for Abstracts: Call contact
 
Registration: Contact Information:
DIA Europe

ELISABETHENANLAGE 25, POSTFACH

4002 BASEL, SWITZERLAND

PHONE: +41 61 225 51 51 b

FAX: +41 61 225 51 52

E-MAIL: DIAEUROPE@DIAEUROPE.ORG

E-mail: diaeurope@diaeurope.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.